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ABSTRACT
Objective: This study was conducted to prove the role of interleukin-4 gene promoter polymorphisms in Graves’ disease patients in M Djamil General 
Hospital Padang, Indonesia.
Methods: This study was conducted from August 2015 until December 2015 in the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, 
West Sumatera, Indonesia. This study involved 15 patients with Graves’ disease and 15 normal subjects. We examined that IL-4 promoter gene 
polymorphism was examined with PCR.
Results: Sequencing examination on IL-4 gene promoter resulted in 2 Single Nucleotide Polymorphism (SNP) motifs, which is rs2243250 and 
rs2070847. IL-4 SNP gene promoter polymorphisms rs2243250 and rs2070847 were found in both patient and control groups. TT is homozygous 
SNP polymorphisms. CT is heterozygous SNP polymorphisms. CC is wild type or no mutation SNP polymorphisms. Based on statistical tests, no 
difference in rs2243250 and rs2070847 SNP polymorphisms was found between patient and control group (p > 0.05).
Conclusion: This study observed no difference in interleukin-4 gene promoter polymorphism between Graves’ disease patients and control group.
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INTRODUCTION
Graves’ disease is a hyperthyroid state characterized by diffuse 
enlargement of thyroid gland due to immunological causes. The 
immunological process that underlies Graves’ disease is the low clonal 
T-cell regulator. The T-cell regulator function is to regulate the balance of 
T-helper 1 (Th1) and T-helper 2 (Th2) cells in antibody production [1-5].
There are several studies linking the genetic role of Graves’ disease. 
There are various genes related to autoimmune thyroid disease. These 
genes control immune responses such as major histocompatibility 
complex genes, T cell receptor genes, and antibody genes and genes 
that encode autoantigen targets in autoimmune thyroid disease. Recent 
studies have found that promoter gene polymorphisms are associated 
with Graves’ disease [6-11].
Cytokines are crucial in the inflammatory response. Genes associated with 
these cytokines are strong candidates to be cause of autoimmune thyroid 
disease. Cytokine related genes include interleukin (IL)-1a, IL-1b, IL-1 
receptor antagonists, IL-1 receptors, IL-4 receptors, IL-6, IL-10, and tumor 
growth factor-β (TGF-β). Research shows that the variant of IL-4 is closely 
related to the development of autoimmune thyroid disease, especially 
Graves’ disease. Variation of the IL-4 gene may be the key to autoimmune 
thyroid disease or other organ-specific autoimmune diseases [9,12].
Due to the important role of interleukin-4 gene promoter 
polymorphisms, this study was conducted to prove the role of this gene 
in Graves’ disease.
MATERIALS AND METHODS
This study was conducted from August 2015 until December 2015 in 
the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, 
West Sumatera, Indonesia. This study involved 15 patients with 
Graves’ disease and 15 normal subjects. Graves’ disease was confirmed 
by measuring free thyroxine (FT4), thyroid-stimulating hormone 
(TSH), and thyrotropin receptor antibody (TRAb). Patients with other 
autoimmune hyperthyroid diseases, chronic infection, and malignancy 
were excluded from the study. All blood samples have taken from these 
study participants for laboratory tests. All patients have provided a 
signed consent. This research has received an ethical approval from the 
Ethics Committee of Medical Faculty of Andalas University.
Examination methods
We examined that IL-4 promoter gene polymorphism was examined 
with PCR.
Statistical analysis
Categorical scale data were written in frequencies and percentages, while 
interval data or ratio scale was written in mean (standard deviation).
RESULTS
There are 15 patients and 15 controls in this study. Average of age in 
patients group is 40.87 (11.23) years. The number of female patients 
in this study is more than male patients, with percentage of women are 
73.3% and men are 26.7%.
Mean FT4 level is 77.89 (72.77) pmol/l, mean serum TSH level is 0.07 
(0.09) UIU/l, and mean TRAb level is 5.23 (4.35) IU/l. Research’s subject 
characteristics are shown in Table 1.
Sequencing examination on IL-4 gene promoter resulted in 2 Single 
Nucleotide Polymorphism (SNP) motifs, which is rs2243250 and 
rs2070847. PCR results of direct DNA sequencing methods for SNP 
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rs2243250 and rs2070847 in samples and controls are shown in 
Table 2.
Table 2 showed that IL-4 SNP gene promoter polymorphisms 
rs2243250 and rs2070847 were found in both patient and control 
groups. TT is homozygous SNP polymorphisms. CT is heterozygous SNP 
polymorphisms. CC is wild type or no mutation SNP polymorphisms. 
Based on statistical tests, no difference in rs2243250 and rs2070847 
SNP polymorphisms was found between patient and control group 
(p > 0.05).
DISCUSSION
In this study, the age range between 31 and 40 years and female sex is 
the most group who experiences Graves’ disease. This is consistent with 
the American Thyroid Association data which explain that although 
Graves’ disease can occur in all ages, it is more common in women than 
men in the 7–8:1 ratio. Like most other autoimmune diseases, female 
sex is the group that most often experiences autoimmune disease. It is 
suspected the role of the hormone estrogen in stimulating antibody and 
autoantibody production through B cells. Estrogen also increases levels 
of IL-4, IL-10, and TGF-β and expression of CD80 and FOXP3 [13-15].
A study of the relationship of rs2243250 polymorphism with Graves’ 
disease in Caucasian populations shows controversial results and 
requires further study in other populations. Many studies analyze 
the relationship between IL-4 polymorphisms and autoimmune 
diseases. However, the results of these studies are inconsistent and 
inconclusive [16].
A meta-analysis study conducted by Shen et al. assessed the 
relationship between IL-4 gene polymorphisms and the risk of thyroid 
autoimmune disease. The results of this study indicate that there is a 
proven relationship in the entire population except in a small subgroup 
of Asia and Caucasians. This study also found an association between 
the polymorphisms of the IL-4 gene rs2243250, rs2070874, and 
rs2243289 with Graves’ disease [16].
Heward et al. investigated the polymorphism of the −590 C/T promoter 
gene in the IL-4 gene. They reported that there was no significant 
difference in the frequency of alleles between the group with Graves’ 
disease (14.3%) and the control group (12%). This study also showed 
that there was no difference in genotype frequency between groups with 
Graves’ disease (26%) compared to the control group (20.3%) [17].
Meanwhile, research conducted by Hunt et al. reported that there was no 
difference in IL-4 gene polymorphism between the group with Graves’ 
disease (6%) and the control group (14%). This study states that the 
T alleles polymorphism of –590 C/T in the IL-4 promoter gene is a 
protective factor against Graves’ disease in the United Kingdom. This is 
indicated by a decrease in the frequency of CT genotypes observed in 
patients with Grave’s disease when compared with control subjects [12].
Several case–control studies showed evidence of a correlation between 
IL-4 intron-3 promoter polymorphisms and various diseases, such 
as rheumatoid arthritis, respiratory infections in children, and early 
dental infections [18]. In a study conducted by Zhu et al., they found 
that genetic variants of the IL-3, IL-4, IL-5, IL-9, and IL-13 genes 
were determinants of the possibility of Graves’ disease in Chinese 
populations [19]. Meanwhile, a study by Nakkuntod et al. in Thailand 
reported that the allele frequency of −589T did not differ between 
Graves’ disease patient and control groups (69% vs. 69.3%). This 
study concluded that gene polymorphisms could not be used as genetic 
markers of disease susceptibility Grave in Thailand population [20].
In this study, polymorphisms were seen in genes with SNP motifs 
rs2243250 and rs2070847. In SNP rs2243250, the most alleles were 
TT (58.3%) in the patient group and CT alleles (60%) in the control 
group, while the SNP rs2070847 obtained that the most alleles were CC 
(66.7%) in the patient group and CT alleles (66.7%) in the control group.
There was no significant difference in the IL-4 gene polymorphism 
between the control group and the Graves’ disease group, with 
p value of 0.693 at SNP rs2243250 and p = 0.311 at SNP rs2070874. 
This is in line with other researches that also did not find differences 
in genotype frequency between the Graves’ disease and the control 
group [12,17,21-23].
CONCLUSION
This study observed no difference in interleukin-4 gene promoter 
polymorphism between Graves’ disease patients and control group, 
suggesting that this polymorphism does not play a role in the genetic 
susceptibility in Graves’ disease.
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